This study will investigate the immediate and longer-term effects of integrated myofascial release therapy on breathing-related outcomes in healthy adults.
Participants will receive integrated myofascial release therapy twice a week for 6 weeks, for a total of 12 treatment sessions. Assessments will be performed before treatment, immediately after the first treatment session, at the end of the 6-week treatment period, and 1 month and 3 months after treatment.
The study will evaluate pulmonary function, cough strength, and chest mobility. The aim is to determine both the immediate response to a single treatment session and whether repeated treatment produces effects that are maintained during follow-up.
Age 18 years or older.
Ability to communicate in Turkish.
Voluntary agreement to participate in the study.
Ability to attend the scheduled assessment and treatment sessions regularly.
Asthma, clinically significant dyspnea, or chronic pulmonary disease.
Influenza, COVID-19, or another acute respiratory tract infection within the previous 6 weeks that may affect respiratory function.
Recent surgery involving the neck, shoulder, or thoracic region.
History of rib fracture or an acute musculoskeletal condition that would make manual therapy inappropriate.
Single group
Other
Other interventionIntegrated myofascial release therapy will be administered twice weekly for 6 weeks, for a total of 12 sessions. Each session will last approximately 20-30 minutes. The intervention will include single arm pull, lateral neck-shoulder myofascial release, and pectoral-anterior chest cross-hand release techniques. Techniques will be applied using slow, low-intensity, pain-free manual contact while following tissue resistance and release. The sequence and target regions will be standardized across sessions.
Change in Xiphoid-Level Chest Expansion
Chest expansion will be measured at the xiphoid/epigastric level using a non-elastic measuring tape. The difference between chest circumference at maximal inspiration and maximal expiration will be calculated in centimeters. Measurements will be repeated using the same anatomical landmarks and standardized participant position across assessment time points.
Change in Forced Vital Capacity (FVC)
Forced vital capacity will be assessed using spirometry and recorded in liters. Participants will perform repeated acceptable forced expiratory maneuvers according to the standardized measurement procedure, and the highest acceptable FVC value will be used for analysis.
Change in Forced Expiratory Volume in 1 Second (FEV1)
Forced expiratory volume in 1 second will be assessed using spirometry and recorded in liters. Participants will perform repeated acceptable forced expiratory maneuvers, and the highest acceptable FEV1 value will be used for analysis.
Change in FEV1/FVC Ratio
The FEV1/FVC ratio will be calculated automatically by the spirometry device from acceptable forced expiratory maneuvers and recorded as a percentage.
Change in Peak Expiratory Flow (PEF)
Peak expiratory flow will be assessed during standardized spirometry maneuvers. The highest technically acceptable PEF value will be recorded and used for analysis, expressed according to the spirometry device output.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
